| A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential |
34 |
| Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress |
20 |
| Developmental Changes in Pharmacokinetics and Pharmacodynamics |
20 |
| A Phase Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment |
18 |
| Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment |
15 |
| Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? |
12 |
| Clinical Pharmacology of the Reversible and Potent P2Y(12) Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects |
12 |
| Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling |
12 |
| The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis |
12 |
| Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System |
12 |
| Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects |
11 |
| Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy |
10 |
| A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents |
10 |
| Clinical Pharmacokinetics of Sulfobutylether-beta-Cyclodextrin in Patients With Varying Degrees of Renal Impairment |
10 |
| Probiotics in Disease Prevention and Treatment |
10 |
| Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance |
9 |
| Opioid Therapy in Acute and Chronic Pain |
9 |
| Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics |
9 |
| Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects |
9 |
| Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes |
9 |
| Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women |
9 |
| Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis |
9 |
| Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil |
9 |
| Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials |
9 |
| A Randomized Double-Blind Controlled Trial of Intravenous Meloxicam in the Treatment of Pain Following Dental Impaction Surgery |
9 |
| FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis |
8 |
| Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis |
8 |
| Drug Transporters Expressed in the Human Placenta and Models for Studying Maternal-Fetal Drug Transfer |
8 |
| Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis |
8 |
| Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection |
8 |
| Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics |
8 |
| Analgesics and Sedatives in Critically Ill Newborns and Infants: The Impact on Long-Term Neurodevelopment |
8 |
| MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease |
7 |
| Effect of Memantine on Serum Levels of Neuron-Specific Enolase and on the Glasgow Coma Scale in Patients With Moderate Traumatic Brain Injury |
7 |
| Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters |
7 |
| Estimating Renal Function in Drug Development: Time to Take the Fork in the Road |
7 |
| Negative Association of Proton Pump Inhibitors With Subsequent Development of Breast Cancer: A Nationwide Population-Based Study |
7 |
| Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies |
7 |
| Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis |
7 |
| Lack of Impact by SCY- a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions |
7 |
| Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia |
7 |
| Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics |
6 |
| Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia |
6 |
| Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment |
6 |
| Evaluation of Model-Based Prediction of Pharmacokinetics in the Renal Impairment Population |
6 |
| Individualized Pharmacokinetic Dosing of Vancomycin Reduces Time to Therapeutic Trough Concentrations in Critically Ill Patients |
6 |
| Oliceridine (TRV130), a Novel G Protein-Biased Ligand at the mu-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model |
6 |
| Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications |
6 |
| Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor |
6 |
| Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects |
6 |
